Uncommon Mutations in Non-Small Cell Lung Cancer (Ongoing)

The series on “Uncommon Mutations in Non-Small Cell Lung Cancer” is edited by Dr. Marco Russano, Department of Medical Oncology, University Campus Bio-Medico of Rome, Rome, Italy.

Read More>>

PCM Annual Report 2020

As we prepare this brief 2020 annual report of Precision Cancer Medicine (PCM), the world is still in the fight against COVID-19 pandemic that has gravely impacted every aspects of our personal and professional lives for over a year. In spite of the complicated and difficult situations, we have continued to work together with you to make some progress in the journal development in 2020.

Read More>>

Evidence and Controversies in the treatment of metastatic NSCLC

The series on “Evidence and Controversies in the treatment of metastatic NSCLC” is edited by Dr. Grace K. Dy, MD, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA. This series has included a collection of debate-style brief editorials, featuring back-to-back pro/con position from different clinical experts in the field.

Read More>>

Non-Small Cell Lung Cancer (NSCLC)

The series “Non-Small Cell Lung Cancer (NSCLC)” was edited by Dr. Alfredo Addeo, Oncology Department, University Hospital Geneva, Geneva, Switzerland and Dr. Giuseppe Banna, Division of Medical Oncology, Cannizzaro Hospital, Catania, Italy.

Read More>>

Lung Cancer In Women: From Epidemiology To Therapy (Ongoing)

This series on “Lung Cancer In Women: From Epidemiology To Therapy” is edited by Dr. Editta Baldini, from Department of Medical Oncology, San Luca Hospital, Lucca, Italy and Dr. Franca Melfi, from Robotic Multispecialty Center for Surgery, University Hospital of Pisa, Pisa, Italy.

Read More>>

Management of Triple Negative Breast Cancer (Ongoing)

This series on “Management of Triple Negative Breast Cancer” is edited by Dr. Jacques Raphael, MD, Department of Oncology, Western University, London, ON, Canada. This series will explore different options, approaches and techniques such as chemotherapy, immunotherapy, adjuvant and neoadjuvant chemotherapy, as well as radiation therapy and biomarkers etc., so as to improve the treatments for triple negative breast cancer.

Read More>>

ALK and ROS-1 NSCLC patients treatment approach based on genomic profile by liquid biopsy (Ongoing)

This series on “ALK and ROS-1 NSCLC patients treatment approach based on genomic profile by liquid biopsy” is edited by Dr. Jesús Corral, Dr. Laura Mezquita, and Dr. Ernest Nadal.

Read More>>

Precision Oncology Tumor Board

Guest Editor: Balazs Halmos, MD
Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA

The Precision Oncology Tumor Board is to provide a global forum for dialogue and education for discussion about the optimal use of biomarker testing in a vast number of emerging clinical settings. An article for this column could be a Case-Based Review, providing a case with educational values and relevant review of the literature and highlighting the level of evidence supporting key decisions. The format of this category is recommended as follows: Introduction, Case Presentation, Tumor Management, Case-related Literature Review and Conclusion. Specific guidelines of this series could be found in the Author Instructions.

Read More>>